ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,674Medicare Part D Prescriptions Filled, Including Refills

Rank: 178 out of 2680

$1.04M Total Retail Price of All Prescriptions

Rank: 56 out of 2680

314 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
98% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New York
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

11% of this provider’s 314 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

1% of this provider’s 9,277 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

55% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$107 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

31 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New York
NEXIUM 365 352 1 19
LOVAZA 278 265 2 47
CRESTOR 251 246 3 15
METOPROLOL SUCCINATE 242 231 4 11
LIDODERM 236 233 5 74
ZOLPIDEM TARTRATE 212 210 6 17
AMLODIPINE BESYLATE 211 206 7 3
DIOVAN 194 194 8 26
SOLARAZE 180 176 9 172
TAMSULOSIN HCL 172 171 10 25
SIMVASTATIN 155 153 11 1
PLAVIX 150 144 12 41
PRAVASTATIN SODIUM 150 139 12 16
VOLTAREN 147 140 14 103
CREON 135 130 15 112
OMEPRAZOLE 135 126 15 2
ATORVASTATIN CALCIUM 134 129 17 10
LOSARTAN POTASSIUM 132 129 18 18
ADVAIR DISKUS 131 114 19 32
FUROSEMIDE 125 124 20 7
BUSPIRONE HCL 105 102 21 174
DIOVAN HCT 101 98 22 54
ALENDRONATE SODIUM 100 82 23 20
NAMENDA 100 95 23 43
CLOPIDOGREL 93 89 25 30
CARVEDILOL 93 92 25 27
METFORMIN HCL ER 89 89 27 53
MECLIZINE HCL 83 81 28 105
COREG CR 81 81 29 292
RANITIDINE HCL 79 72 30 35
EXFORGE HCT 78 78 31 375
KETOCONAZOLE 77 61 32 244
MIRTAZAPINE 75 73 33 48
NITROGLYCERIN PATCH 75 75 33 171
SYNTHROID 74 69 35 39
SPIRONOLACTONE 73 73 36 86
AMMONIUM LACTATE 71 71 37 118
DETROL LA 71 71 37 217
METOPROLOL TARTRATE 66 66 39 8
RANEXA 66 55 39 173
LIPITOR 65 65 41 78
BENICAR 63 60 42 122
DONEPEZIL HCL 61 60 43 28
ISOSORBIDE MONONITRATE ER 61 61 43 57
FINASTERIDE 61 61 43 80
CELEBREX 59 53 46 75
AMITIZA 58 58 47 190
TRAMADOL HCL 58 50 47 33
METFORMIN HCL 57 57 49 6
RAMIPRIL 57 47 49 49
CHLORHEXIDINE GLUCONATE 54 54 51 166
VESICARE 51 48 52 214
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 18, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.